This morning, Merck (NYSE: MRK) unveiled first-quarter earnings, which dropped 57% thanks to a drop in both drug sales and income from its cholesterol medicine partnerships. Excluding charges, Merck brought in 74 cents per share in quarterly earnings. The results were a full three cents short of the consensus estimate.Turning to revenue, Merck reported $5.39 billion - an 8% drop from a year ago. The consensus estimate for quarterly revenue was $5.77 billion, so the results were far short of the bar set by the Street.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
